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Available online xxxxDetermination of the speciﬁc type of thyroid cancer is crucial for the prognosis and selection of treatment of this
malignancy. However, in some cases appropriate classiﬁcation is not possible based on histopathological features
only, and it might be supported by molecular biomarkers. Here we aimed to characterize molecular proﬁles of
different thyroid malignancies using mass spectrometry imaging (MSI) which enables the direct annotation of
molecular features with morphological pictures of an analyzed tissue. Fifteen formalin-ﬁxed parafﬁn-
embedded tissue specimens corresponding to ﬁve major types of thyroid cancer were analyzed by MALDI-MSI
after in-situ trypsin digestion, and the possibility of classiﬁcation based on the results of unsupervised segmen-
tation of MALDI images was tested. Novel method of semi-supervised detection of the cancer region of interest
(ROI) was implemented. We found strong separation of medullary cancer from malignancies derived from thy-
roid epithelium, and separation of anaplastic cancer from differentiated cancers. Reliable classiﬁcation of medul-
lary and anaplastic cancers using an approach based on automated detection of cancer ROI was validated with
independent samples.Moreover, extraction of spectra from tumor areas allowed the detection ofmolecular com-
ponents that differentiated follicular cancer and twovariants of papillary cancer (classical and follicular).We con-
cluded thatMALDI-MSI approach is a promising strategy in the search for biomarkers supporting classiﬁcation of
thyroid malignant tumors. This article is part of a Special Issue entitled: MALDI Imaging, edited by Dr. Corinna
Henkel and Prof. Peter Hoffmann.






Thyroid nodules are very common in the general population and can
be detected by palpation or ultrasonographic survey in about 5% of the
adult population. Malignant tumors occur in 5–10% of such nodules,
hence thyroid cancer is the most common endocrine malignancy and
comprises 1–3% of all cancers worldwide [1]. The majority of thyroid
carcinomas originate from follicular epithelial cells and include well-
differentiated papillary thyroid carcinomas (PTC; N70% of all thyroid
malignancies) and follicular thyroid carcinomas (FTC; 10–20% ofteom-Center, Ruhr-University
y.
a), corinna.henkel@isas.de
., Molecular proﬁles of thyroid
ys. Acta (2016), http://dx.doi.thyroid malignancies), as well as anaplastic (undifferentiated) carcino-
mas (ATC) which are the most aggressive thyroid malignancy (1–2%
of thyroid cancers);moreover, two variants of PTC can be distinguished:
classical (PTC-CV) and follicular (PTC-FV). Furthermore, medullary thy-
roid carcinoma (MTC) that is derived from the parafollicular C-cells and
has neuroendocrine features, comprises 3–5% of thyroid cancers. The
types of thyroid cancer are distinguished based on histopathological
features, and this classiﬁcation is the primary step in the assessment
of prognosis and selection of a treatment [2–5]. Themajority of patients
with thyroid cancer are initially diagnosed based on the ﬁne needle as-
piration cytology (FNAC) of thyroid nodules [6,7]. Further diagnosis is
performed based on a histopathological intraoperative examination of
the resected thyroid tissue. However, in some cases cytological and his-
tological patterns are ambiguous and proper classiﬁcation is problemat-
ic [8]. For example, among important challenges in the diagnostics of
thyroid cancer there is differentiation between benign follicularcancer subtypes: Classiﬁcation based on features of tissue revealed by
org/10.1016/j.bbapap.2016.10.006
Table 1
Description of clinical material.
Code Pathology Stage Sex Age Surgery Content
MTC-1 MTC pT1bN1bMx M 47 2003 C, T
MTC-2 MTC pT2N0Mx M 51 2004 C, T, F
MTC-3 MTC pT2(m)N1bMx M 60 2006 C, T, F
ATC-1 ATC pT4bN1bMx F 75 2002 C, N
ATC-2 ATC pT4bN1aMx M 62 2004 C, N
ATC-3 ATC pT4aN1bMx M 14 2000 C, N, T
FTC-1 FTC pT1bNxMx F 65 1999 C, F
FTC-2 FTC pT3N0Mx M 57 1996 C, F
FTC-3 FTC pT2NxMx F 44 2011 C, F
PTC_CV-1 PTC CV pT2N1aMx F 58 2004 C, M, A, F
PTC_CV-2 PTC CV pT1bNxMx M 67 2002 C, M, A, F
PTC_CV-3 PTC CV pT3(m)NxMx F 64 2002 C, T, M, F
PTC_FV-1 PTC FV pT2N1bMx M 20 2003 C, M, A, F
PTC_FV-2 PTC FV pT2N1aMx F 31 2004 C, T, F
PTC_FV-3 PTC FV pT1bN1bMx M 9 2000 C, A, F
Pathology: MTC — medullary thyroid carcinoma; ATC — anaplastic thyroid carcinoma;
FTC— follicular thyroid carcinoma; PTC_CV— papillary thyroid carcinoma, classic variant;
PTC_FV — papillary thyroid carcinoma, follicular variant; patient's sex: F — female, M —
male; tissue sample content: C— carcinoma, N— necrosis, T— normal thyroid, M—mus-
cle, A — adipose tissue, F — ﬁbrous tissue.
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cinoma, which share several histological features [9,10].
Currently, classiﬁcation of thyroid cancer based on histopathological
patterns could be supported by molecular biomarkers, including
markers identiﬁedwith the use of high-throughput “omics” approaches
[11–16]. The most numerous and advanced studies are based on muta-
tion and gene expression proﬁling. This type of studies revealed several
gene expression signatures, some of them associated with mutations in
cancer driver genes, which enable us to distinguish different types of
thyroid cancers or malignant tumors from benign lesions [17–21]. A
fewproteomics studies also identiﬁed proteinswhose differential abun-
dances could allow the discrimination of cancerous and normal thyroid
tissue [22,23], malignant and benign follicular lesions [24,25], or papil-
lary and follicular cancers [26]. Similarly, metabolomics analysis of thy-
roid tissue could also reveal molecular signatures characteristic for
different types of thyroid lesions [27]. It is noteworthy, however, that
the presence of non-tumor tissue in analyzedmaterial canmarkedly af-
fect composition and performance of molecular signatures built for the
classiﬁcation of thyroid lesions. Therefore, performing molecular analy-
sis using micro-dissected material should always be considered [28].
Moreover, molecular intra-tumor heterogeneity is still a rather under-
researched aspect in the thyroid cancer ﬁeld [29]. Hence, the direct
combination of knowledge of molecular proﬁles with morphological
features of an analyzed tissue would be a valuable approach in the
search for molecular classiﬁers of thyroid tumors.
Mass spectrometry imaging (MSI) is an emerging approach in bio-
medical research and it is recently evolving into a powerful tool in the
study of various types of diseases. Themajor beneﬁt ofMSI is the possibil-
ity to combine molecular and morphological information, since molecu-
lar images are spatially resolved and well-correlated with the respective
histological images. Moreover, different molecular species, e.g. proteins,
peptides, lipids, drugs and their metabolites can be imaged, signiﬁcantly
broadening the amount of information derived from a tissue [30–33].
Among many applications of MSI there was molecular characterization
and classiﬁcation of different types of solid tumors [34–38]. The particular
advantage ofMSI in cancer research is the allocation ofmolecular proﬁles
to speciﬁc cell types, such as cancerous, preneoplastic or inﬂammatory.
Moreover, MSI could be used in the studies of the interface of tumor
and normal tissue (tumor niche) and intra-tumor heterogeneity
[39–44]. In recent years there were also a few attempts to implement
MSI in the studies of thyroid cancer. MSI analysis of cytological material
from FNA biopsies revealed proteomic proﬁles characteristic for different
types of thyroid cancer [45–46]. Recently Pagni et al. showed thatMALDI-
MSI was capable of distinguishing between papillary thyroid cancer and
benign thyroid tumors using proteomic signatures of cytological samples
[47]. Furthermore, MSI analysis of thyroid tissue allowed detection of
proteins discriminating papillary cancer from normal thyroid [48].
Hence, these preliminary studies indicated the promising potential of
the MSI approach in the search for molecular signatures that could be
used in the classiﬁcation of thyroid malignancies. Here, we aim to use
MALDI-MSI to identify cancer type-speciﬁc features of formalin-ﬁxed
parafﬁn-embedded (FFPE) tissue samples representative for ﬁve types
of thyroid cancers, and to apply molecular signatures revealed by MSI
for classiﬁcation of malignant tissue specimens. Furthermore, we
established and implemented an original semi-supervised approach to
the detection of the cancer region of interest (ROI).
2. Methods
2.1. Clinical material
Postoperative tissue collected during thyroidectomy and stored as
formalin-ﬁxed parafﬁn-embedded material was used in the study. Tis-
sue samples represented ﬁve types of thyroid malignancies: anaplastic
thyroid carcinoma (ATC), follicular thyroid carcinoma (FTC), classic var-
iant of papillary thyroid carcinoma (PTC-CV), follicular variant ofPlease cite this article as:M. Pietrowska, et al., Molecular proﬁles of thyroid
mass spectrometry imaging, Biochim. Biophys. Acta (2016), http://dx.doi.papillary thyroid carcinoma (PTC-FV), andmedullary thyroid carcinoma
(MTC); the material was collected from three patients in each group
(Table 1 presents detailed description of the clinical material). Thyroid-
ectomy was performed between 1996 and 2011 at Maria Skłodowska-
Curie Memorial Cancer Center and Institute of Oncology in Gliwice.
The studywas approved by the Institutional Ethics Committee (Approv-
al No. KB/430-49/12). Tissue material was re-inspected by an experi-
enced pathologist before the study; the selected samples contained
50–90% of cancer tissue (small amounts of normal thyroid, muscles
and connective tissue were also present).
2.2. Sample preparation
FFPE tissue samples were sectioned (10 μm) using a rotary micro-
tome (HM 340E, Thermo Fisher Scientiﬁc, Waltham, MA, USA) at
room temperature and placed on ITO coated glass slides (Bruker
Daltonik, Bremen, Germany). Tissue sections were subjected to
dewaxing and rehydration in histology glass containers via consecutive
washes (5 min each) in: xylene (twice), isopropanol, ethanol 99.8%,
90%, 70% and 50% EtOH, and ﬁnally in TBS buffer. The rehydration step
was followed by heat-induced antigen retrieval: sections were heated
at 97 °C for 30 min in a retrieval solution (20 mM Tris/EDTA buffer,
pH 9). In the next step tissue sections were coated with a solution of
trypsin (20 μg in 200 μL of 50 mM NH4HCO3; Promega, Madison, USA)
with the use of an automatic spraying device (ImagePrep, Bruker),
then incubated for 18 h at 37 °C in a humid chamber. Optical images
were registered (1200 dpi), and then samples were coated with meth-
anolic solution of 2,5-dihydroxybenzoic acid (50% methanol, 30
mg/mLDHB, 1% TFA). Thematrixwas deposited using ImagePrep device
with Bruker's standard matrix coating program with doubled phase 5
(DHB_for_Digest_nsh01).
2.3. MALDI imaging
Matrix-coated sections were subjected to imaging with the use of a
MALDI-TOF/TOF ultraﬂeXtreme (Bruker) spectrometer equipped with
a smartbeam II™ laser operating at 1 kHz repetition rate. Ions were ac-
celerated at 25 kVwith PIE timeof 100 ns. Spectrawere recorded in pos-
itive reﬂectron mode within m/z range of 600–4000 and externally
calibrated with Peptide Calibration Standard II (Bruker). A raster
width of 100 μm was applied with a large laser focus and 500 shots
were collected from each ablation point (random walk was activated
in the scanning procedure with 50 shots at a raster spot). Compass 1.4
for FLEX series (Bruker) was employed for spectra acquisition,cancer subtypes: Classiﬁcation based on features of tissue revealed by
org/10.1016/j.bbapap.2016.10.006
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was washed off the glass slides with 70% ethanol (two washes, 1 min
each) and the sections were stained with hematoxylin and eosin, then
scanned and used for image co-registration using ﬂexImaging version
4.1 software (Bruker).2.4. Spectra processing and identiﬁcation of spectral components
Spectrum preprocessing included resampling to commonm/z chan-
nels followed by detection and removal of a baseline (baseline detection
employed the envelope spanned over 10% intensity quantiles calculated
for every 200 m/z windows approximated with the use of spline tech-
nique). The spectra were then aligned, TIC normalized and averaged
over all preparations. The mean spectrumwas decomposed into Gauss-
ian Mixture Model (GMM) as described in detail elsewhere [49]; the
model componentswere used to deﬁne spectral features. For every spe-
ciﬁc (x,y) point in every preparation and for every component in GMM
model a convolution of a normalizedMALDI spectrumand a component
of Gaussian function was performed giving an integral of the pointwise
multiplication of these two functions as the GMM component-related
feature value.2.5. Deglomerative ik-means based grouping of tissue preparations
GMM-based features were used during the iterative divisive ik-
means segmentations (DivIK) of all 15 samples together according to
the approach described in detail elsewhere [50]. The feature abundance
ﬁltering [51] was applied to remove peptides with intensities at the
noise level. During each iteration of the developed algorithm, the most
informative features within a tissue region (cluster) were identiﬁed
with the use of the same ﬁltration technique, yet signal decomposition
was performed in the domain of variance of peak abundance across
the cluster. K-means algorithm with intelligent setting of initial condi-
tions (named ik-means) was applied in the stepwise splitting. Dunn's
index was used to decide on the number of clusters in a particular split-
ting. During the succeeding steps, each cluster found in the previous
step was split independently of the others. The splitting was performed
till the cluster's size (measured by the number of spectra included)
reached a priori assumed limit of 0.1% of the original number of (x,y)
points in the dataset or the third level of splittingwas achieved. The ob-
tained clusters were then characterized by their centroids calculated
over all GMM-based features. The ﬁnal set of centroids, representing
molecularly homogenous regions within tissue sample, was then used
in further analyses. After each step of the deglomerative segmentation,
cluster enrichment analysis was performed within each sample
allowing the identiﬁcation of clusters over represented in particular
samples. Χ2 test of independence was applied to verify the hypothesis.
If any outlying group of such samples was found, it was excluded from
the next step of splitting.2.6. Step-down segmentation and expanded ROI
TheDivIK-based step-down segmentation of datawas performed for
each sample separately to obtain basic (core) homogenous segments
further represented by their centroids. The algorithm's stop criterion
was related to cluster size only, i.e. 0.1% of original number of spectra
in the sample. The correlation-based dissimilarity index was estimated
between each basic segment and a sample-speciﬁc expert-deﬁned can-
cer reference area. The distribution of such dissimilarity indices was
subjected to the GaussianMixtureModeling [51], which allowed the es-
timation of the dissimilarity thresholds separating groups of segments
that were the most similar and the most dissimilar to the reference
area. Segments allocated to the “cancer-similar” group constructed the
cancer “extended Region of Interest” (exROI).Please cite this article as:M. Pietrowska, et al., Molecular proﬁles of thyroid
mass spectrometry imaging, Biochim. Biophys. Acta (2016), http://dx.doi.2.7. Cancer classiﬁcation
The initial set of 15 samples was randomly split into two balanced
subsets: training and testing ones — the random drawing was done in-
dependently for each cancer type keeping 2:1 ratio between training
and testing sets. Two classiﬁcation approaches were compared.
2.7.1. Classical approach
The training dataset included 58,890 spectra from the tumor regions
manually segmented by an expert (supervised approach); each spec-
trum was labeled with a cancer type. Five “One (cancer type) versus
Other (cancer types)” (OvO)binary classiﬁerswere built using the logis-
tic regression framework with Bayes factor as a criterion for model se-
lection. The value of Bayes factor showing at least strong evidence
(BF N 103/2) was set as the inclusion criterion in the forward stepwise
procedure of model construction. The regression models were then ap-
plied to calculate the probability that a particular “cancerous” spectrum
belonged to a particular cancer type; the spectrum was classiﬁed as
“belonged to cancer type” if the calculated probability was N0.5. The
maximum probability criterion was applied, where the type of tested
sample is enforced by the leading cancer type assigned to the spectra
within the tumor region. Only samples with N50% of spectra being of
the same typewere classiﬁed (others were labeled as “undetermined”).
The performance of the obtained classiﬁerswas checkedusing the train-
ing and testing sample sets.
2.7.2. Novel approach
Cancer exROIs and corresponding “Not Cancer” exROIs from 10
training samples (semi-supervised approach)deﬁned the starting train-
ing data set, and were used to build the “Cancer versus Not Cancer”
(CvNC) binary classiﬁer. The classiﬁer trainingwas performed in the do-
main of 2478 homogenous similar-to-cancer basic segments, each rep-
resented by its centroid calculated in the domain of 3216 GMM
components. The logistic regression framework with all the settings
similar to those from classical approach was applied. The obtained re-
gression model was then applied to calculate the probability of spec-
trum to be cancer-similar: the spectrum was classiﬁed as “actual
cancer” if the estimated probability was N0.5. Together with the CvNC
classiﬁer, ﬁve additional “One versus Others” (OvO) binary classiﬁers
were also built using the same framework. The performance of the ob-
tained classiﬁers was checked using the training and testing sample
sets. Additional set of 4 new samples was included for the independent
validation of the OvO classiﬁers. In contrary to samples from the testing
set, these sampleswere not consideredwhile theGMMmodelwas built.
The rawspectra from the independent validation setwere aligned to the
average spectrumof the initial 15 samples andnormalized to their aver-
age TIC value, then the components' abundanceswere found by the con-
volution of 3216 GMM masks. Two steps of classiﬁcation were
performed: during the ﬁrst one “actual cancer” spectra were found
with the use of general CvNC classiﬁer. The second step employed all
ﬁve OvO classiﬁers to predict the cancer type of all cancer spectra.
2.8. Supervised detection of GMM-based components differentiating
between types of cancer
Both expert-deﬁned cancer regions and cancer exROIs were used in
the search for GMM-based components discriminating between the
types of cancer. Components that putatively corresponded to four
major tryptic fragments of trypsin, namely 842.51, 1045.56, 2211.10
and 2283.18 Da, were removed from the analysis. Parametric Tukey-
Kramer tests were applied to verify hypotheses on equality of abun-
dance level of spectral components between cancer types. The conser-
vative Bonferroni correction for multiple testing together with
additional condition on large effect size measured by the Cohen's d sta-
tistics to be higher than 0.8 were applied to avoid large false discovery
rates.cancer subtypes: Classiﬁcation based on features of tissue revealed by
org/10.1016/j.bbapap.2016.10.006
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spectra
The centroids of the 3rd level clusters obtained in global divisive ik-
means-based segmentation were subjected to agglomerative merging
by hierarchical clustering technique with average linkage function and
Pearson's correlation coefﬁcient serving as a similarity measure. Similar
hierarchical agglomeration was done in the domain of average GMM-
based features (the mean spectra).
3. Results
There were ﬁfteen FFPE tissue specimens representative for ﬁve
types of thyroid cancer, namely medullary (MTC), anaplastic (ATC)
and three types of differentiated cancers (FTC, PTC-CV and PTC-FV)
(Table 1), analyzed byMALDI-MSI. The selected specimensmostly com-
prised of cancerous tissue and aminor proportion of other tissues (nor-
mal thyroid, muscles and connective tissue), which was veriﬁed by an
experienced pathologist based on histological features. Tissue samples
were analyzed after in-situ trypsin digestion within 600–4000 Da
mass range, hence the majority of detected components (with masses
above 800 Da) corresponded to tryptic fragments of proteins present
in cancer tissue (including their isotopic envelope). There were 3216
components identiﬁed, which comprehensively described molecular
proﬁles of all analyzed tissue samples. Complete information about
the abundance of these components was used in both supervised and
unsupervised analyses aimed at the estimation of differences between
tissue specimens of different types of thyroid carcinomas; Fig. 1 sche-
matically represents the implemented approaches.
In the ﬁrst approach tissue specimens were compared using an un-
supervised approach without any information on the histopathological
structure of the samples. Above 200,000 spectra registered for all 15
samples were subjected to a clustering using our own recursive algo-
rithm. Distribution of clusters detected during the deglomerative seg-
mentation was used to estimate general similarities among different
tissue samples (Fig. 2A; complete results of the performed segmenta-
tion are presented in Supplementary Fig. S1). In the initial analysis allFig. 1. Different approaches implemented
Please cite this article as:M. Pietrowska, et al., Molecular proﬁles of thyroid
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clustering (i) in Fig. 2A. Two separate groups of samples were revealed
(χ2 test p-value b 1e−08), one of them consisting of medullary cancer
(MTC) samples and the other one including all other samples. In theﬁrst
level of this segmentation the cluster of spectra characteristic for MTC
contributed to the majority of all spectra registered for the three MTC
samples (89%, 52%, and 58%, respectively) and was negligible in the
case of other samples (b1%). The “outlying” MTC samples were re-
moved from subsequent cluster analysis; clustering (ii) in Fig. 2A. This
step of deglomerative splitting also revealed two groups of samples
(with p-value for overrepresentation p b 1e−04): the ﬁrst group of
samples consisted of three samples corresponding to anaplastic carcino-
ma (ATC), whereas the other group contained all other samples corre-
sponding to differentiated cancer (FTC, PTC-CV and PTC-FV). In the
ﬁrst level of this segmentation the cluster of spectra characteristic for
ATC contributed to 61%–97% of all spectra registered for ATC samples,
and to 1%–37% of all spectra registered for the remaining samples. For
the subsequent analysis the three ATC samples were removed and the
next step of deglomerative sample grouping was performed; clustering
(iii) in Fig. 2A. However, distributions of clusters in the remaining sam-
ples were similar and meaningful discrimination between the types of
differentiated cancer was not possible. Furthermore, the contribution
of each cluster to the composition of a particular sample was used to
classify all 15 tissue specimens. A dendrogram reﬂecting the similarity
of samples based on the distribution of clusters detected at the 3rd
level of global segmentation is shown in Fig. 3A. We observed separa-
tion of MTC samples and ATC samples in distinct branches of the den-
drogram, yet samples corresponding to differentiated cancers were
mixed all together. We concluded that the overall features of the sam-
ples, which were mirrored in the distribution of clusters detected in a
whole specimen, allowed discrimination of the most distinctive types
of thyroid cancer — MTC and ATC. However, samples of well-
differentiated cancers (FTC, PTC-CV and PTC-FV) cannot be discriminat-
ed based on this type of analysis.
In further analyses we implemented additional expert-based infor-
mation about the location of tissue regions corresponding to tumor.
Cancerous regions were identiﬁed and marked by a pathologist inin classiﬁcation of thyroid cancers.
cancer subtypes: Classiﬁcation based on features of tissue revealed by
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Fig. 2.MALDI-MSI analysis of different types of thyroid cancer. Panel A – Results of the deglomerative grouping of samples. Subsequent clustering experiments (i), (ii) and (iii) were
performed for all tissue samples (global segmentation), after removal of MTC samples, and after removal of ATC samples, respectively; marked are clusters detected at the 1st level of
segmentation: (i) - yellow and navy blue, (ii) – green and yellow, (iii) – violet and blue. Panel B - Areas corresponding to actual tumor were marked in red on H&E stained tissue
preparations; yellow dots correspond to the reference cancer areas. Panel C – Expanded ROIs were established in each sample individually for cancer, not cancer and undeﬁned
(indeterminate) areas; only spectra from cancer and not cancer exROIs of samples from the training set were used to train the “cancer versus not cancer” classiﬁer. Panel D –
Heatmaps of local cancer probability estimated basing on the general “cancer vs. not cancer” classiﬁer. Abbreviations: MTC – medullary thyroid carcinoma; ATC – anaplastic thyroid
carcinoma; FTC – follicular thyroid carcinoma; PTC-CV – papillary thyroid carcinoma, classic variant; PTC-FV – papillary thyroid carcinoma, follicular variant.
5M. Pietrowska et al. / Biochimica et Biophysica Acta xxx (2016) xxx–xxxeach sample (Fig. 2B). Spectra exported from these expert-deﬁned
tumor areas (ca. 35–85% of registered spectra)were used for supervised
analysis aimed at the identiﬁcation of components discriminating dif-
ferent types of thyroid cancer; the average tumor-speciﬁc spectra com-
puted for each cancer type are presented in Supplementary Fig. S2. First,
we testedwhether the overall proﬁles of tumor-related spectra could be
used to assess differences between particular types of thyroidmalignan-
cies. Vectors of average abundances of GMM-based features were com-
puted for each sample, and then a dendrogram reﬂecting the detected
similarities was calculated by hierarchical agglomeration (Fig. 3B). We
observed the separation ofMTC samples and ATC samples from samplesFig. 3. Similarity between samples corresponding to ﬁve different types of thyroid cancer. Pan
segmentation). Panel B – Dendrogram based on average tumor-speciﬁc spectra. Abbreviat
follicular thyroid carcinoma; PTC-CV -papillary thyroid carcinoma, classic variant; PTC-FV – pa
Please cite this article as:M. Pietrowska, et al., Molecular proﬁles of thyroid
mass spectrometry imaging, Biochim. Biophys. Acta (2016), http://dx.doi.corresponding towell-differentiated cancers thatwere present in a sep-
arate branch of the dendrogram, yet further separation of the latter
samples into speciﬁc types was not possible. We hypothesized that po-
tential components having different abundances between the samples
of FTC, PTC-CV and PTC-FV were apparently over-dominated by more
frequent “non-differentiating” components, hence discrimination of
well-differentiated thyroid cancer could not be performed based on a
general molecular proﬁle reﬂected in averaged spectra. However, abun-
dance of components characteristic for MTC and ATC was sufﬁciently
high, which allowed their discrimination also based on general proﬁles
of the registered spectra.el A – Dendrogram based on general distribution of clusters (at the third level of global
ions: MTC – medullary thyroid carcinoma; ATC – anaplastic thyroid carcinoma; FTC –
pillary thyroid carcinoma, follicular variant.
cancer subtypes: Classiﬁcation based on features of tissue revealed by
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based on spectra extracted from expert-deﬁned tumor regions, a classi-
ﬁcation approach was implemented as the next step. All individual
spectra were analyzed using ﬁve different “One (cancer type) versus
(all) Other (cancer types)” binary classiﬁers. All 15 tissue samples
were split randomly into two sets — a training set (10 specimens; 2
samples from each cancer type) and a testing set (5 specimens; 1 sam-
ple from each cancer type). The result of sample classiﬁcation was con-
sidered meaningful if N50% of spectra extracted from tumor area could
be assigned to a given type of cancer (an individual spectrum could be
classiﬁed positively asmore than one type, hence the resulting percent-
ages may not add to 100%). We observed reliable classiﬁcation of all
samples in the training set. However, in the testing set only samples of
MTC and PTC-FV were classiﬁed properly, while the other samples
were undetermined (ATC and FTC) or misclassiﬁed (PTC-FV); the re-
sults are summarized in Table 2.
Moreover, we tested whether molecular features of tissue regions
detected by unsupervised segmentation of MSI images could be used
for classiﬁcation of thyroid cancers. For this purpose we implemented
a novel method for semi-supervised detection of ROI representing the
actual cancer region. For each sample a step-down segmentation was
performed that resulted in a large number of small homogeneous clus-
ters (600–1800 clusters per sample), which established “basic seg-
ments” and reﬂected the intrinsic heterogeneity of specimens. Spectra
registered in each basic segment were represented by its centroid,
which allowed for more than 10-fold reduction in dimensionality
(16,617 segments overall) and facilitated further computation. Then,
in each specimen a small “reference” region was marked by a patholo-
gist (about 2–4% of the specimen's area) which corresponded to clearly
deﬁned foci of cancer cells (excluding necrosis and other tumor-related
areas). Similarity of each basic segment to such cancer reference region
was assessed afterwards, and subsequently sets of basic segments were
identiﬁed in each sample individually using a statistical approach: “can-
cer similar”, “not cancer similar” and “indeterminate”. Segments in each
set were combined to form an expanded ROI (exROI) for cancer, not
cancer and unclassiﬁed tissue (Fig. 2C). Subsequent classiﬁcation of can-
cer types was performed in two steps allowing (i) semi-supervised de-
tection of cancer regions based on general features of thyroid
malignancies, and then (ii) identiﬁcation of cancer types based on fea-
tures of detected cancer regions only. In the ﬁrst step, spectra extracted
from all cancer exROIs and not cancer exROIs (irrespective of cancerTable 2
Results of cancer type classiﬁcation performedwith classiﬁers based on expert-deﬁned tumor ar
a given type of cancer by the “One versus Others” approach. True and false results of classiﬁcat
Sample set Sample Classiﬁcation by expert-deﬁned tumor area
MTC ATC FTC PTC_CV PTC_FV Result
Training MTC-1 99.7% 1.1% b0.1% 0.3% b0.1% MTC
MTC-2 99.6% 0.2% 0.2% 0.1% b0.1% MTC
ATC-1 0% 94.1% 0.3% 0% b0.1% ATC
ATC-3 0% 85.1% 0.4% 9.3% 0.1% ATC
FTC-2 0% 4.8% 93.9% 6.5% 0.6% FTC
FTC-3 0% 0.4% 98.4% 4.6% 12.9% FTC
PTC_CV-1 0.1% 15.4% 7.5% 82.4% 5.5% PTC_C
PTC_CV-2 0% 1.3% 0.2% 91.6% 1.2% PTC_C
PTC_FV-2 0% 1.4% 0.4% 23.6% 91.6% PTC_F
PTC_FV-3 0% 4.4% 0.5% 8.5% 76.1% PTC_F
Testing MTC-3 98.3% 0.9% 13.7% 9.4% 0.2% MTC
ATC-2 b0.1% 16.4% 6.4% 8.9% 0.1% Undet
FTC-1 0% 15.1% 0.5% 31.1% 35.2% Undet
PTC_CV-3 0% b0.1% 23.2% 36.1% 60.9% PTC_F
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classiﬁer, which allowed automated detection of cancer areas in all tis-
sue specimens. The probability of classiﬁcation of an individual spec-
trum as cancer-similar is depicted in Fig. 2D in a form of heatmaps;
areas containing spectra that showed probability of such classiﬁcation
higher than 50% were considered as actual cancer regions. Afterwards,
all individual spectra from cancer regions were analyzed by ﬁve “One
versus Others” binary classiﬁers using the same split of samples in the
training and the testing set (10 and 5 samples, respectively) as de-
scribed in the previous section. Positive classiﬁcation of all samples in
the training set was observed (similar to classiﬁcation based on
expert-deﬁned tumor region). In the testing set three samples were
classiﬁed properly — MTC, ATC and PTC-FV, while two samples were
misclassiﬁed (FTC and PTC-CV); detailed results are presented in
Table 2. This classiﬁcation approach was further validated using four
new independent tissue specimens. In this independent validation set
there were two samples classiﬁed properly —MTC and ATC, while two
samples representing differentiated epithelium-derived cancer (FTC
and PTC-CV) were misclassiﬁed (Table 2 and Fig. 4). We concluded
that the classiﬁcation approach based on automated detection of ex-
panded cancer ROIs allowed a reliable classiﬁcation of medullary and
anaplastic cancer, which was validated using independent samples.
Hence, the results of this innovative approach seemed superior to the
results of a more classical approach based on spectra extracted from
expert-deﬁned tumor regions. However, this method also failed to dis-
criminate samples of differentiated epithelium-based cancers.
Finally, we searched for spectral components with signiﬁcantly dif-
ferent abundances between the compared types of thyroid malignan-
cies. The pairwise comparisons were performed between the ﬁve
types of thyroid cancers (using all 15 samples from the initial sample
set) based on spectra from either expert-deﬁned tumor regions or
from expanded cancer ROIs described above (detailed results in Supple-
mentary Table S1); examples of such components are presented in Sup-
plementary Fig. S3. As one could expect, the highest number of
differentiating components was observed between C-cell-derived and
epithelium-derived cancers; about 25% of detected components dis-
criminated MTC from all other types of thyroid cancer. Differences
among the types of epithelium-derived cancers were less frequent.
There were about 8%, 5% and 2% of detected components that differen-
tiated ATC fromboth subtypes of PTC, FTC, and all types of differentiated
cancers, respectively (in the analysis of spectra from expert-deﬁnedeas and expanded cancer ROI. Shown is percentage of spectra in cancer regions assigned to
ion are marked in bold and italics, respectively.
Classiﬁcation by expanded cancer ROI Actual type
MTC ATC FTC PTC-CV PTC-FV Result
93.1% 4.2% 0.2% 0.2% 0.5% MTC MTC
89.3% 4.5% 1.6% 2.1% 3.2% MTC MTC
b0.1% 98.1% 5.8% 1.4% 1.6% ATC ATC
b0.1% 62.1% 5.6% 11.1% 6.9% ATC ATC
0.4% 4.2% 81.3% 10.9% 2.5% FTC FTC
0% 1.9% 94.2% 4.4% 3.5% FTC FTC
V b0.1% 5.1% 14.4% 78.4% 15.7% PTC_CV PTC_CV
V b0.1% 5.6% 14.9% 66.2% 25.8% PTC_CV PTC_CV
V b0.1% 4.1% 6.1% 4.1% 86.8% PTC_FV PTC_FV
V 0% 15.4% 2.3% 11.4% 71.6% PTC_FV PTC_FV
56.2% 6.1% 11.6% 0.4% 3.8% MTC MTC
ermined b0.1% 57.1% 33.4% 14.8% 12.9% ATC ATC
ermined 0% 11.2% 16.3% 28.3% 38.4% Undetermined FTC
V b0.1% 11.3% 28.7% 33.3% 66.9% PTC_FV PTC_CV
V b0.1% 8.8% 74.4% 3.6% 81.1% PTC_FV PTC_FV
b0.1% 34.9% 4.1% 22.1% 17.5% Undetermined FTC
50.3% 7.2% 40.8% 0.6% 18.2% MTC MTC
0% 54.4% 3.5% 12.9% 35.4% ATC PTC_CV
0% 62.7% 8.4% 5.3% 22.3% ATC ATC
cancer subtypes: Classiﬁcation based on features of tissue revealed by
org/10.1016/j.bbapap.2016.10.006
Fig. 4. Results of classiﬁcation of cancer types by the ﬁve “OvO” classiﬁers using the semi-
supervised approach based on exROIs. Panel A – Location of cancer-derived spectra
assigned to a particular cancer type in exemplary samples from the training set;
samples' areas marked in gray corresponded to cancer exROIs. Panel B – Classiﬁcation of
samples in the independent validation set. Presented are heatmaps of probability of
classiﬁcation of spectra as cancer-derived (upper row, scale the same as in Fig. 2D), and
location of cancer-derived spectra assigned to a particular cancer type. Validation
samples V-1, V-2, V-3 and V-4 corresponded to FTC, MTC, PTC-CV and ATC, respectively.
Abbreviations: MTC – medullary thyroid carcinoma; ATC – anaplastic thyroid
carcinoma; FTC – follicular thyroid carcinoma; PTC-CV -papillary thyroid carcinoma,
classic variant; PTC-FV – papillary thyroid carcinoma, follicular variant.
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ed FTC from both subtypes of PTC. Furthermore, components that dis-
criminated between PTC-CV and PTC-FV were also detected. It is
noteworthy that discriminatory components detected in analyses
based on spectra from expert-deﬁned tumor areas and from cancer
exROIs overlapped substantially (Table 3). Moreover, the analysis
based on exROIs reduced unexpectedly large difference between sam-
ples of PTC-FV and all remaining samples, observed in spectra from
expert-deﬁned areas, which made subsequent comparisons more
credible.Please cite this article as:M. Pietrowska, et al., Molecular proﬁles of thyroid
mass spectrometry imaging, Biochim. Biophys. Acta (2016), http://dx.doi.4. Discussion
One of the major advantages of MALDI-MSI lies in its capability to
measure abundances of molecular species in the histological context.
This approach allows unbiased analysis of intact tissue sections, avoiding
sample homogenization and preserving its anatomical features. As a re-
sult molecular information speciﬁc for particular tissue regions can be re-
vealed without the necessity of their physical separation. Moreover, the
ability to perform unsupervised analysis of imaging data allows the dis-
crimination of tissue regions which could not be revealed by classical
morphology-based approaches [30–36]. Complex composition of tissues
and organs results in the possible “contamination” of a target of interest
with products of adjacent or intruding tissues, which is a potential prob-
lem inmany types ofmolecular studies. Therefore, a study focused specif-
ically on cancer proteome could be challenged by the necessity of the
physical separation of cancer cells from other tissue components such
as necrotic areas, connective tissue ormuscles by using lasermicrodissec-
tion to provide the best quality of results [52]. In this study the MALDI-
MSI approach was used to search for molecular features characteristic
for different types of thyroidmalignancies.Molecular signatures of cancer
were established using spectra exported from speciﬁc tissue areas de-
ﬁned by a pathologist as a tumor based on their morphological features,
which might be called a “virtual microdissection”. Precise combination
of a molecular proﬁle with its histological context requires annotation
of MSI data with a morphological picture using the same section of
FFPEmaterial. However, histological inspection of H&E stained tissue fol-
lows MALDI-MSI, hence microscopically analyzed material is potentially
damaged and distorted by earlier procedures. Moreover, cancer cells
could form micro-foci embedded within other types of cells or may
have morphology resembling normal tissue. As a consequence, some de-
tails of cancerous tissue structure could be missed or improperly
interpretedduring apathologist re-inspection of tissue samples previous-
ly subjected to MALDI-MSI. To overcome this potential problem we pro-
pose an approach that combines expert knowledge and unsupervised
segmentation of MSI maps. A small “reference” cancer area is detected
by the pathologist that contains actual cancer cells and is devoid of ne-
crotic cells and components of tumor niche. The whole tissue specimen
is subjected to in-depth segmentationwhich allows us to detect small ho-
mogenous clusters, called “basic segments”, which reﬂect the intrinsic
heterogeneity of tissue. Then, basic segments showing a high degree of
molecular (spectral) similarity to the cancer reference area are detected
and merged as a “cancer extended ROI” to be used in further analyses.
This semi-supervised approach helped retrieve information from small
foci of the cancer cell and to use all spectra potentially reﬂectingmolecu-
lar features of cancer. Simultaneously, confounding information related
to small foci of normal or necrotic cells frequently intruding into the can-
cer area was removed. Moreover, our approach offers other important
beneﬁts, which include substantial dimension reduction in large datasets
resulting in lower computation load required for their analyses, aswell as
less laborious andmore crediblework of an expert in detection of speciﬁc
areas present in a heterogeneous tissue specimen. Hence, universal
merits of the proposed approach make it useful for any other MSI-
based study oriented on detection and characterization of disease-
affected tissue regions.
In this work molecular proﬁles of tissue sub-regions revealed by su-
pervised, semi-supervised and unsupervised analyses of MALDI-MSI
data were used aiming to classify different types of thyroid cancers. All
implemented approaches allowed the reliable discrimination of sam-
ples containing medullary thyroid carcinoma. MTC is a thyroid malig-
nancy uniquely derived from neuroendocrine parafollicular C-cells. Its
molecular proﬁle is apparently distinct from other thyroidmalignancies
derived from follicular epithelial cells, and includes expression of calci-
tonin and other hormone-related proteins [53]. The abundance of mo-
lecular factors characteristic for MTC appeared sufﬁcient to allow
detection of this type of cancer based on the results of unsupervised seg-
mentation of MSI-generated data, as well as for proper classiﬁcation ofcancer subtypes: Classiﬁcation based on features of tissue revealed by
org/10.1016/j.bbapap.2016.10.006
Table 3
Number of spectral components with signiﬁcantly different abundances between areas
corresponding to different types of thyroid cancer. Each linewith bolded characters repre-
sents the number of differentiating components which overlapped in pairwise compari-
son listed in the lines above.
Difference between
cancer types






MTC vs. ATC 1581 (49%) 1868 (58%) 1548 (48%)
MTC vs. FTC 1995 (62%) 2040 (64%) 1892 (59%)
MTC vs. PTC-CV 1639 (51%) 1759 (55%) 1572 (49%)
MTC vs. PTC-FV 1792 (56%) 1770 (55%) 1595 (50%)
MTC vs. all no-MTC 804 (25%) 1108 (34%) 757 (24%)
ATC vs. PTC-CV 300 (9,3%) 275 (8.6%) 215 (6.7%)
ATC vs. PTC-FV 1927 (59%) 663 (21%) 643 (20%)
ATC vs. all PTC 258 (8.0%) 241 (7.5%) 179 (5.6%)
ATC vs. FTC 171 (5.3%) 80 (2.5%) 73 (2.3%)
ATC vs. all no-ATC 73 (2.3%) 53 (1.7%) 40 (1.2%)
FTC vs. PTC-CV 85 (2.6%) 103 (3.2%) 60 (1.9%)
FTC vs. PTC-FV 1342 (42%) 405 (13%) 389 (12%)
FTC vs. all PTC 55 (1.7%) 92 (2.9%) 50 (1.6%)
PTC-CV vs. PTC-FV 1182 (37%) 77 (2.4%) 72 (2.2%)
Abbreviations:MTC—medullary thyroid carcinoma; ATC— anaplastic thyroid carcinoma;
FTC— follicular thyroid carcinoma; PTC-CV— papillary thyroid carcinoma, classic variant;
and PTC-FV— papillary thyroid carcinoma, follicular variant.
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ful observation becauseMTC frequently represents a follicular pattern of
growth, hence its histopathological examination should be frequently
supplemented with molecular diagnostics for proper discrimination
from epithelium-derived follicular tumors [54]. Another type of thyroid
cancer that could be discriminated thanks to the analysis of MALDI-MSI
datawas undifferentiated anaplastic cancer (ATC), whichwas separated
from differentiated cancers based on distribution of the detected clus-
ters as well as general composition of its molecular proﬁle (i.e. average
spectrum registered by MALDI-MSI). Moreover, proper classiﬁcation of
this malignancy was also validated with independent samples. Signiﬁ-
cant differences in proteomic proﬁles between undifferentiated and dif-
ferentiated thyroid carcinomas could be predicted based on robust
differences in gene expression proﬁles among these malignancies,
which apparently involves dysregulation of matrix metalloproteinase
pathways in ATC [55]. On the other hand, analyses based on molecular
proﬁles detected during MALDI-MSI could neither discriminate nor
classify three types of differentiated thyroid carcinomas. However, it
should be noted that histopathological diagnosis of PTC-CV, PTC-FV
and FTC is strictly based onmicroscopic examination of tissuemorphol-
ogy (e.g. structure of cell nuclei) [5,9]. Relatively low spatial resolution
of MALDI-MSI used in the present study (100 μm) did not allow the ad-
dressing ofmicroscopic features of tissues. This limitation, togetherwith
the relative similarity of general molecular proﬁles detected by MALDI-
MSI in differentiated thyroid cancers, could contribute to the low dis-
criminatory power of the classiﬁcation methods used in the present
work. However, the feasibility of classiﬁcation of thyroid malignancies
using MSI analysis of tissue specimens might be reassessed if methods
based on molecular proﬁles used data recorded with a higher spatial
resolution or were combined with approaches addressing the texture
of samples.
Molecular differences between differentiated thyroid carcinomas –
papillary and follicular – were observed at the level of gene expression
proﬁles [21] and cancer metabolome [15]. Moreover, differences be-
tween PTC and FTC were also reported at the level of cancer proteome.
A set of 9 proteins isolated from tissue extracts, including 14-3-3 iso-
forms, ANXA5, TUBA1B, PRX6, A1AT, SELENBP1, and PDIp, could dis-
criminate PTC and FTC with 100% positive predictive value [26].
However, proteomic signatures speciﬁc for classical and follicular vari-
ants of PTC, which could support differential diagnosis of these two var-
iants of papillary cancer, were not reported. The MALDI-MSI approach
was previously applied to analyze cytological smears of FNA thyroidPlease cite this article as:M. Pietrowska, et al., Molecular proﬁles of thyroid
mass spectrometry imaging, Biochim. Biophys. Acta (2016), http://dx.doi.specimens. There were several spectral components revealed that dis-
criminated different types of thyroid tumors: benign nodules, Hurthle
cell follicular adenomas, PTC andMTC [45–47]. Moreover, a few spectral
components discriminating classical and follicular variants of PTC were
also detected using cytological material [46]. Here we found that analy-
sis of spectra exported from tumor regions allowed detection of several
components with signiﬁcantly different abundances between FTC, PTC-
CV and PTC-FV. We concluded that MALDI-MSI that allows retrieval of
molecular proﬁles speciﬁc for tumor regions, which could be called “vir-
tual microdissection”, followed by the identiﬁcation of differentiating
proteins by on-tissueMS/MS is a promising approach to detect potential
biomarkers to support diagnosis of differentiated thyroid tumors.
Supplementary data to this article can be found online at doi:10.
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